Opus Genetics is trading at $4.71, up 5.49%, with no clear company-specific announcement identified for October 9.
- The latest company release found was September 9 clinical-trial news.
- Jones Trading raised its price target on October 6, but that earlier action does not establish the cause of this session’s gain.
- Biotech was up 2.50%, a plausible supportive backdrop; broader major-index gains were modest. No volume information was provided.